STBD1

Summary

STBD1 (starch binding domain 1, HGNC:24854) is a protein-coding gene on chromosome 4q21.1, encoding Starch-binding domain-containing protein 1 (O95210). Acts as a cargo receptor for glycogen.

Enables enzyme binding activity and glycogen binding activity. Involved in glycophagy and intracellular transport. Located in T-tubule; endoplasmic reticulum; and perinuclear region of cytoplasm.

Source: NCBI Gene 8987 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 1 total
• MANE Select transcript: NM_003943

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24854
Approved symbol	STBD1
Name	starch binding domain 1
Location	4q21.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ41801, GENX-3414
Ensembl gene	ENSG00000118804
Ensembl biotype	protein_coding
OMIM	607406
Entrez	8987

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000237642

RefSeq mRNA: 1 — MANE Select: NM_003943 NM_003943

CCDS: CCDS3578

Canonical transcript exons

ENST00000237642 — 2 exons

Exon	Start	End
ENSE00001025285	76306733	76306989
ENSE00002024062	76309144	76311130

Expression profiles

Bgee: expression breadth ubiquitous, 138 present calls, max score 91.93.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.2218 / max 594.9924, expressed in 1455 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
48331	6.3380	1349
48330	2.4178	726
48328	0.7298	230
48329	0.6659	201
48327	0.0703	32

Top tissues by expression

139 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
gastrocnemius	UBERON:0001388	91.93	gold quality
muscle of leg	UBERON:0001383	91.63	gold quality
skeletal muscle organ	UBERON:0014892	91.53	gold quality
hindlimb stylopod muscle	UBERON:0004252	89.18	gold quality
skeletal muscle tissue	UBERON:0001134	88.79	gold quality
right lobe of liver	UBERON:0001114	87.56	gold quality
liver	UBERON:0002107	86.10	gold quality
muscle tissue	UBERON:0002385	84.42	gold quality
heart left ventricle	UBERON:0002084	82.99	gold quality
right atrium auricular region	UBERON:0006631	82.51	gold quality
heart	UBERON:0000948	81.99	gold quality
islet of Langerhans	UBERON:0000006	80.81	gold quality
subcutaneous adipose tissue	UBERON:0002190	80.77	gold quality
adipose tissue	UBERON:0001013	80.26	gold quality
popliteal artery	UBERON:0002250	79.92	gold quality
tibial artery	UBERON:0007610	79.91	gold quality
apex of heart	UBERON:0002098	79.82	gold quality
left coronary artery	UBERON:0001626	79.44	gold quality
mucosa of transverse colon	UBERON:0004991	79.26	gold quality
omental fat pad	UBERON:0010414	79.25	gold quality
right coronary artery	UBERON:0001625	78.33	gold quality
transverse colon	UBERON:0001157	77.95	gold quality
descending thoracic aorta	UBERON:0002345	77.55	gold quality
lower esophagus muscularis layer	UBERON:0035833	77.23	gold quality
lower esophagus	UBERON:0013473	77.16	gold quality
smooth muscle tissue	UBERON:0001135	76.89	gold quality
thoracic aorta	UBERON:0001515	76.56	gold quality
colon	UBERON:0001155	76.44	gold quality
ascending aorta	UBERON:0001496	76.43	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	76.43	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	5.49

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

73 targeting STBD1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489
HSA-MIR-548O-5P	99.94	71.24	3488
HSA-MIR-548W	99.94	71.24	3488
HSA-MIR-548Y	99.94	71.28	3514
HSA-MIR-374A-5P	99.90	71.34	2923

Literature-anchored findings (GeneRIF, showing 4)

• Atg8 interacting motif (AIM) in Stbd1 is necessary for GABARAPL1 binding. (PMID:21893048)
• results demonstrate that Stbd1 plays a dominant role in glycogen transport to lysosomes in liver and that the N-terminal transmembrane region and the C-terminal CBM20 domain are critical for this function. (PMID:27358407)
• Model-based analysis uncovers mutations altering autophagy selectivity in human cancer. (PMID:34059679)
• Decoding the molecular mechanism of selective autophagy of glycogen mediated by autophagy receptor STBD1. (PMID:39236246)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	stbd1	ENSDARG00000098408
mus_musculus	Stbd1	ENSMUSG00000047963
rattus_norvegicus	Stbd1	ENSRNOG00000002218

Protein

Protein identifiers

Starch-binding domain-containing protein 1 — O95210 (reviewed: O95210)

Alternative names: Genethonin-1, Glycophagy cargo receptor STBD1

All UniProt accessions (1): O95210

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a cargo receptor for glycogen. Delivers its cargo to an autophagic pathway called glycophagy, resulting in the transport of glycogen to lysosomes.

Subunit / interactions. Interacts with the ATG8 family proteins GABARAP and GABARAPL1. Interacts with several glycogen-associated proteins, such as GYS2 (liver glycogen synthase), GDE (glycogen debranching enzyme), GBE1 (glycogen branching enzyme 1) and EPM2A (Laforin).

Subcellular location. Preautophagosomal structure membrane. Endoplasmic reticulum membrane. Cell membrane. Sarcolemma. T-tubule.

Tissue specificity. Expressed at high level in skeletal and cardiac muscles. Moderately expressed in liver and placenta. No expression is found in pancreas, kidney or lung. Present in skeletal muscle, heart and placenta (at protein level).

Post-translational modifications. Ubiquitinated, which leads to proteasomal degradation.

Domain organisation. The LIR motif (LC3-interacting region) is required for the interaction with the ATG8 family protein GABARAPL1. The C-terminal CBM20 domain is required for the interaction with glycogen and glycogen-associated proteins.

RefSeq proteins (1): NP_003934* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002044	CBM20	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR013784	Carb-bd-like_fold	Homologous_superfamily
IPR034838	CBM20_genethonin_1	Domain

Pfam: PF00686

UniProt features (24 total): modified residue 9, compositionally biased region 4, mutagenesis site 3, topological domain 2, region of interest 2, chain 1, transmembrane region 1, domain 1, short sequence motif 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
8X8A	X-RAY DIFFRACTION	1.53
8X8K	X-RAY DIFFRACTION	2.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95210-F1	58.44	0.28

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (9): 65, 117, 148, 175, 188, 194, 210, 211, 220

Mutagenesis-validated functional residues (3):

Position	Phenotype
203	abolishes interaction with gabarapl1.
206	abolishes interaction with gabarapl1.
293	abolishes gys2- and glycogen-binding, and leads to rapid degradation.

Function

Pathways and Gene Ontology

Reactome pathways

12 pathways

ID	Pathway
R-HSA-6798695	Neutrophil degranulation
R-HSA-8980692	RHOA GTPase cycle
R-HSA-9013404	RAC2 GTPase cycle
R-HSA-9013405	RHOD GTPase cycle
R-HSA-9013408	RHOG GTPase cycle
R-HSA-9013423	RAC3 GTPase cycle
R-HSA-162582	Signal Transduction
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System
R-HSA-194315	Signaling by Rho GTPases
R-HSA-9012999	RHO GTPase cycle
R-HSA-9716542	Signaling by Rho GTPases, Miro GTPases and RHOBTB3

MSigDB gene sets: 142 (showing top): REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_LYSOSOMAL_TRANSPORT, GOBP_VACUOLE_ORGANIZATION, GOCC_SECRETORY_GRANULE, PEREZ_TP63_TARGETS, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_VACUOLAR_TRANSPORT, BROWNE_HCMV_INFECTION_16HR_UP, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_MACROAUTOPHAGY, GOBP_GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY, GOBP_POLYSACCHARIDE_CATABOLIC_PROCESS, UEDA_PERIFERAL_CLOCK, SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A4, TGCTGAY_UNKNOWN

GO Biological Process (7): glycogen catabolic process (GO:0005980), lysosomal transport (GO:0007041), glycophagy (GO:0061723), substrate localization to autophagosome (GO:0061753), glycogen metabolic process (GO:0005977), autophagy (GO:0006914), vesicle-mediated transport (GO:0016192)

GO Molecular Function (7): enzyme binding (GO:0019899), polysaccharide binding (GO:0030247), cargo receptor activity (GO:0038024), glycogen binding (GO:2001069), starch binding (GO:2001070), protein binding (GO:0005515), carbohydrate binding (GO:0030246)

GO Cellular Component (9): endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), plasma membrane (GO:0005886), membrane (GO:0016020), T-tubule (GO:0030315), phagophore assembly site membrane (GO:0034045), perinuclear region of cytoplasm (GO:0048471), tertiary granule membrane (GO:0070821), ficolin-1-rich granule membrane (GO:0101003)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
RHO GTPase cycle	5
Innate Immune System	1
Immune System	1
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	1
Signaling by Rho GTPases	1
Signal Transduction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
polysaccharide binding	2
binding	2
cytoplasm	2
membrane	2
secretory granule membrane	2
tertiary granule	2
glycogen metabolic process	1
glucan catabolic process	1
vacuolar transport	1
glycogen catabolic process	1
macroautophagy	1
autophagosome assembly	1
establishment of localization in cell	1
energy reserve metabolic process	1
glucan metabolic process	1
catabolic process	1
transmembrane transport	1
process utilizing autophagic mechanism	1
transport	1
cellular process	1
protein binding	1
carbohydrate binding	1
molecular_function	1
vesicle-mediated transport	1
molecular adaptor activity	1
endomembrane system	1
intracellular membrane-bounded organelle	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cell periphery	1
sarcolemma	1
phagophore assembly site	1
ficolin-1-rich granule	1

Protein interactions and networks

STRING

680 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
STBD1	F5GZY7	F5GZY7	970
STBD1	GABARAPL2	P60520	691
STBD1	CCDC62	Q6P9F0	616
STBD1	AGL	P35573	613
STBD1	GABARAP	O95166	607
STBD1	EPM2A	O95278	605
STBD1	CALCOCO2	Q13137	577
STBD1	SQSTM1	Q13501	548
STBD1	OPTN	Q96CV9	546
STBD1	ACMSD	Q8TDX5	539
STBD1	NBR1	Q14596	529
STBD1	GYG1	P46976	490
STBD1	GYG2	O15488	487
STBD1	MCCC1	Q96RQ3	479
STBD1	SYT12	Q8IV01	448

IntAct

48 interactions, top by confidence:

A	B	Type	Score
GABARAPL1	STBD1	psi-mi:“MI:0407”(direct interaction)	0.850
STBD1	GABARAPL1	psi-mi:“MI:0915”(physical association)	0.850
GABARAP	STBD1	psi-mi:“MI:0407”(direct interaction)	0.760
GABARAP	STBD1	psi-mi:“MI:0915”(physical association)	0.760
STBD1	GABARAP	psi-mi:“MI:0914”(association)	0.760
GABARAPL2	IPO5	psi-mi:“MI:0914”(association)	0.690
STBD1	GABARAPL2	psi-mi:“MI:0407”(direct interaction)	0.680
GABARAPL2	STBD1	psi-mi:“MI:0915”(physical association)	0.680
GABARAPL1	IPO5	psi-mi:“MI:0914”(association)	0.590
GABARAP	IPO5	psi-mi:“MI:0914”(association)	0.590
KASH5	STBD1	psi-mi:“MI:0915”(physical association)	0.560
STBD1	KASH5	psi-mi:“MI:0915”(physical association)	0.560
MAP1LC3B	STBD1	psi-mi:“MI:0407”(direct interaction)	0.540
MAP1LC3B	STBD1	psi-mi:“MI:0915”(physical association)	0.540
KLRG2	GXYLT2	psi-mi:“MI:0914”(association)	0.530
STBD1	MID1	psi-mi:“MI:0914”(association)	0.530
PRKAB2	STBD1	psi-mi:“MI:0914”(association)	0.530
PPP1R3C	STBD1	psi-mi:“MI:0914”(association)	0.530
PYGB	STBD1	psi-mi:“MI:0914”(association)	0.530
MAP1LC3A	STBD1	psi-mi:“MI:0407”(direct interaction)	0.440
ATF7IP	STBD1	psi-mi:“MI:0915”(physical association)	0.370
GABARAPL1	GABARAP	psi-mi:“MI:0914”(association)	0.350
GABARAPL2		psi-mi:“MI:0914”(association)	0.350
GABARAPL1		psi-mi:“MI:0914”(association)	0.350
GABARAP		psi-mi:“MI:0914”(association)	0.350

BioGRID (193): CCDC155 (Two-hybrid), STBD1 (Affinity Capture-RNA), STBD1 (Affinity Capture-MS), GYG1 (Affinity Capture-MS), GYS2 (Affinity Capture-MS), GYS1 (Affinity Capture-MS), GABARAP (Affinity Capture-MS), GABARAPL1 (Affinity Capture-MS), PYGB (Affinity Capture-MS), MID1 (Affinity Capture-MS), WDFY1 (Affinity Capture-MS), GYG2 (Affinity Capture-MS), AMY1C (Affinity Capture-MS), EPM2A (Affinity Capture-MS), COL4A2 (Affinity Capture-MS)

ESM2 similar proteins: A2ALU4, A6NMK8, B1ASB6, B2RQL2, F6WEQ6, O00220, O14763, O35305, O95210, P16382, P20333, P24394, P25119, P28908, P36941, P50284, P97525, Q0VET5, Q13651, Q3TYD6, Q3U0P1, Q5PQK4, Q5SX79, Q5ZK13, Q60846, Q63257, Q66JV7, Q68CR7, Q6GQV1, Q6P1D7, Q6PHB0, Q6PJW8, Q6WG24, Q6ZRS4, Q76N32, Q80WY6, Q80XI1, Q863Z5, Q8BLK9, Q8BX35

Diamond homologs: D8Q9M3, O95210, P36914, Q2QTC2, Q5FVN1, Q6ZY51, Q8C7E7, A0A059WGE7, A0A0X1KHF9, A0A151V4J3, P22998, Q0CGA6, Q5B1W7, Q81BR3, Q9YEC5

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 34 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Macroautophagy	6	27.7×	7e-06

GO biological processes:

GO term	Partners	Fold	FDR
autophagosome maturation	5	56.6×	2e-06
mitophagy	5	51.3×	2e-06
autophagosome assembly	5	36.2×	9e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

1 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	1
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

385 predictions. Top by Δscore:

Variant	Effect	Δscore
4:76309139:CTTA:C	acceptor_loss	1.0000
4:76309141:TA:T	acceptor_loss	1.0000
4:76309142:A:AG	acceptor_gain	1.0000
4:76309142:A:AT	acceptor_loss	1.0000
4:76309142:AG:A	acceptor_loss	1.0000
4:76309143:G:GA	acceptor_gain	1.0000
4:76309143:G:GG	acceptor_gain	1.0000
4:76309143:GA:G	acceptor_gain	1.0000
4:76309143:GAGC:G	acceptor_gain	1.0000
4:76309133:T:A	acceptor_gain	0.9900
4:76309143:GAGCA:G	acceptor_gain	0.9900
4:76306987:CAGGT:C	donor_loss	0.9800
4:76306990:G:T	donor_loss	0.9800
4:76307792:C:T	donor_gain	0.9800
4:76307975:TTGAA:T	donor_gain	0.9800
4:76309141:TAGA:T	acceptor_gain	0.9500
4:76308822:G:GG	donor_gain	0.9400
4:76309136:T:G	acceptor_gain	0.9400
4:76309142:AGAG:A	acceptor_gain	0.9400
4:76309139:CTTAG:C	acceptor_gain	0.9300
4:76309140:TTAG:T	acceptor_gain	0.9300
4:76309141:TAG:T	acceptor_gain	0.9300
4:76309142:AGA:A	acceptor_gain	0.9300
4:76309143:G:T	acceptor_gain	0.9300
4:76309135:A:AG	acceptor_gain	0.8900
4:76309140:TTAGA:T	acceptor_gain	0.8800
4:76307862:G:GA	donor_gain	0.8700
4:76308737:AC:A	donor_gain	0.8700
4:76308821:A:AG	donor_gain	0.8700
4:76306986:CCAGG:C	donor_loss	0.8500

AlphaMissense

2356 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:76309884:T:A	W321R	0.996
4:76309884:T:C	W321R	0.996
4:76309726:T:C	F268S	0.991
4:76309925:G:C	W334C	0.991
4:76309925:G:T	W334C	0.991
4:76309923:T:A	W334R	0.989
4:76309923:T:C	W334R	0.989
4:76309725:T:C	F268L	0.988
4:76309727:C:A	F268L	0.988
4:76309727:C:G	F268L	0.988
4:76309800:T:A	W293R	0.986
4:76309800:T:C	W293R	0.986
4:76309802:G:C	W293C	0.985
4:76309802:G:T	W293C	0.985
4:76309886:G:C	W321C	0.983
4:76309886:G:T	W321C	0.983
4:76309988:G:C	W355C	0.980
4:76309988:G:T	W355C	0.980
4:76309885:G:C	W321S	0.979
4:76309890:T:C	F323L	0.979
4:76309891:T:C	F323S	0.979
4:76309892:T:A	F323L	0.979
4:76309892:T:G	F323L	0.979
4:76309768:C:A	A282E	0.978
4:76309921:G:C	R333P	0.976
4:76309986:T:A	W355R	0.976
4:76309986:T:C	W355R	0.976
4:76309889:G:C	K322N	0.974
4:76309889:G:T	K322N	0.974
4:76306782:T:A	W5R	0.973

dbSNP variants (sampled 300 via entrez): RS1000182804 (4:76305194 A>T), RS1000466703 (4:76308295 T>A), RS1000786600 (4:76306677 G>A,T), RS1000859234 (4:76307716 C>T), RS1001119857 (4:76308912 A>G), RS1001302329 (4:76306470 T>C), RS1001685665 (4:76310204 GCA>G,GCACA), RS1002280214 (4:76308205 G>GTT), RS1002588633 (4:76307152 A>C,T), RS1002716351 (4:76308012 C>G,T), RS1003076957 (4:76309811 C>T), RS1003294698 (4:76308175 A>G), RS1003314024 (4:76306633 C>A,G,T), RS1004152337 (4:76307616 C>T), RS1004413064 (4:76307185 C>T)

Disease associations

OMIM: gene MIM:607406 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST000528_2	Parkinson’s disease	4.000000e-07

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

52 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, increases expression, increases methylation	4
bisphenol A	decreases expression, increases expression	2
Tetrachlorodibenzodioxin	increases expression	2
Cyclosporine	decreases expression, increases expression	2
Aflatoxin B1	affects expression, decreases expression	2
Cadmium Chloride	increases expression, decreases expression	2
FR900359	increases phosphorylation	1
bisphenol F	increases expression	1
2,4,6-tribromophenol	decreases expression	1
lasiocarpine	decreases expression	1
triphenyl phosphate	affects expression	1
chlortoluron	decreases expression	1
decabromobiphenyl ether	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
zinc chloride	decreases reaction, increases expression	1
sodium arsenite	decreases expression	1
cobaltous chloride	increases expression, decreases reaction	1
tetrabromobisphenol A	decreases expression	1
resorcinol	increases expression	1
ciglitazone	affects binding, increases expression	1
di-n-butylphosphoric acid	affects expression	1
NCS 382	increases expression	1
CGP 52608	affects binding, increases reaction	1
bisphenol B	increases expression	1
abrine	decreases expression	1
pentabrominated diphenyl ether 100	increases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
bisphenol AF	increases expression	1
Resveratrol	increases expression, affects cotreatment	1
Temozolomide	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.